Inactive Instrument

Other languages Jaguar Health Inc Nasdaq

Equities

US47010C3007

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Venture Life renews revolving credit facility with Santander and HSBC	Apr. 19
Jaguar Health, Inc. Appoints Catherine Miller Collis to the Role of Senior Vice President of Growth Strategy	Apr. 18
Wall Street Set to Open Sharply Lower Wednesday as Inflation Rises More Than Expected	Apr. 10
Exchange-Traded Funds Down, Equity Futures Higher Pre-Bell Wednesday Ahead of Fed Meeting Minutes	Apr. 10
Top Premarket Gainers	Apr. 10
Jaguar Health, Inc. Appoints Massimo Radaelli, PhD, as President of Jaguar International	Apr. 03
Jaguar Health, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01
Jaguar Health Reaches Agreement With FDA on Design, Conduct of Medicine Study	Feb. 15
Jaguar Health, Inc. Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea in Dogs	Feb. 15
Top Premarket Gainers	Jan. 26
Napo Pharmaceuticals, Inc. Announces Majority of Subjects in Placebo-Controlled Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Chose to Continue on to Continue on to Stage II	Dec. 11
FDA Approves Renewal of Canalevia-CA1, Jaguar Health?s Drug for Chemotherapy-Induced Diarrhea in Dogs	Dec. 04
Sector Update: Health Care Stocks Higher Late Tuesday Afternoon	Nov. 21
Sector Update: Health Care Stocks Rise Tuesday Afternoon	Nov. 21
Jaguar Health's Napo Pharmaceuticals Awaits Data on Phase 3 Trial of Crofelemer; Shares Fall	Nov. 21
Jaguar Health, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14
Jaguar Health Gets Additional 180-Day Grace Period to Regain Nasdaq Compliance	Nov. 08
Jaguar Health, Inc. Announces Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome	Nov. 01
Jaguar Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
Napo Pharmaceuticals Submits Funding Application to BARDA for NP-300 Development	23-08-09

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Jaguar Health Inc Nasdaq

Equities

US47010C3007

Other languages

Filters